Skip to main content
Elsevier
View Cart

Progress in Medicinal Chemistry

  • 1st Edition, Volume 62 - November 17, 2023
  • Latest edition
  • Editors: Jonathan Bentley, Tilly Bingham
  • Language: English

Progress in Medicinal Chemistry, Volume 62 provides a review of eclectic developments in medicinal chemistry, with each chapter written by an international board of author… Read more

World Book Day celebration

Where learning shapes lives

Up to 25% off trusted resources that support research, study, and discovery.

Explore resources

Description

Progress in Medicinal Chemistry, Volume 62 provides a review of eclectic developments in medicinal chemistry, with each chapter written by an international board of authors.

Key features

  • Provides extended, timely reviews of topics in medicinal chemistry
  • Contains targets and technologies relevant to the discovery of tomorrow’s drugs
  • Presents analyses of successful drug discovery programs

Readership

Everyone interested in the strategy and practice of the preclinical phases of the creation of new medicines. Those wishing to understand the drivers of drug design or expand their knowledge of therapeutic target classes

Table of contents

1. Antibody Drug Conjugates Beyond Cytotoxic PayloadsAdrian Hobson2. Biophysical Screening and Characterisation in Medicinal ChemistryTilly Bingham3. Covalent Fragment LibrariesDavid Mann

Product details

  • Edition: 1
  • Latest edition
  • Volume: 62
  • Published: November 17, 2023
  • Language: English

About the editors

JB

Jonathan Bentley

Jonathan Bentley is a VP, Scientific Director at Evotec in the Discovery Chemistry department in Abingdon UK. He is responsible for the scientific strategy on multiple collaborations and provides strategic leadership and support for scientific delivery across multi-disciplinary drug discovery programs. Within Evotec, he leads the cross-functional global Design Evolution initiative. He joined Evotec as a Project Leader in 2007 and was promoted to VP in 2020. Prior to Evotec, he was a Research Leader at the Psychiatry Centre of Excellence in Drug Design for GSK, Verona for 3.5 years after spending the formative phase of his industrial career at Vernalis in Reading, UK for 7 years. He has contributed to the identification of multiple clinical and preclinical candidates as project leader, or as part of multidisciplinary drug discovery teams in collaboration with international scientific and strategic partners. He has a PhD in Synthetic Organic Chemistry from the University of Bristol, sponsored by SmithKline Beecham (1995). He spent a year in a post-doctoral position at University of Cape Town, supported by Schering AG (1995-6). He has worked on projects across many different therapeutic areas including Oncology, Inflammation, Pain, CNS (Anxiety, Depression, Drug Dependence, Schizophrenia, Insomnia, Neurodegeneration), Metabolic Diseases and Women‘s Health. He has enjoyed working on multiple target classes including agonists, antagonists, PAMs and NAMs of GPCRs from all classes, diverse enzyme inhibitors and activators, and ion channel blockers, openers, and modulators, as well as phenotypic endpoints. He was the first recipient of the RSC / SCI Capps-Green-Zomaya award in 2004.
Affiliations and expertise
VP, Scientific Director, Evotec, Discovery Chemistry Department, Abingdon, UK

TB

Tilly Bingham

Tilly (Matilda) Bingham is a drug discoverer with over 20 years’ experience of working in the pharmaceutical R&D sector in ‘large pharma’ (Organon, Schering-Plough, MSD), Biotech (Redx Pharma), CRO (Concept Life Sciences) and is currently Executive in Residence at Cumulus Oncology. Tilly’s early career was spent working as a medicinal chemist in CNS therapeutic areas where her research focussed on design strategies for getting small molecule therapeutics across the blood brain barrier for targets including the GPCRs OX2R, V1R and CGRP. Then, as Head of Research and Operations at Redx Pharma she oversaw the discovery and development of oncology and fibrosis clinical candidates, including the clinical candidate porcupine inhibitors RXC004 (oncology), RXC006 (AZD5055, fibrosis), Pan RAF inhibitor (JZP815) and FDA approved BTK inhibitor Pirtobrutinib. As VP Science and Chief Scientific Officer at the UK CRO Concept Life Sciences she oversaw multiple research programmes and the development of new research capability across the group. In her current role as Executive in Residence at Cumulus Oncology Tilly is employing her significant expertise in pre-clinical drug discovery to accelerate oncology innovation to key value inflection points.

Affiliations and expertise
Cumulus Oncology

View book on ScienceDirect

Read Progress in Medicinal Chemistry on ScienceDirect